Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 73 (9), 1845-58

The Renewed Battle Against RAS-mutant Cancers


The Renewed Battle Against RAS-mutant Cancers

Fuquan Zhang et al. Cell Mol Life Sci.


The RAS genes encode for members of a large superfamily of guanosine-5'-triphosphate (GTP)-binding proteins that control diverse intracellular signaling pathways to promote cell proliferation. Somatic mutations in the RAS oncogenes are the most common activating lesions found in human cancers. These mutations invariably result in the gain-of-function of RAS by impairing GTP hydrolysis and are frequently associated with poor responses to standard cancer therapies. In this review, we summarize key findings of past and present landmark studies that have deepened our understanding of the RAS biology in the context of oncogenesis. We also discuss how emerging areas of research could further bolster a renewed global effort to target the largely undruggable oncogenic RAS and/or its activated downstream effector signaling cascades to achieve better treatment outcomes for RAS-mutant cancer patients.

Keywords: Autophagy; Cancer therapeutics; HRAS; KRAS; Kinases; NRAS; Signaling; Small GTPases.

Similar articles

See all similar articles

Cited by 12 PubMed Central articles

See all "Cited by" articles


    1. Genes Dev. 2003 Dec 15;17(24):3112-26 - PubMed
    1. J Biol Chem. 1999 Mar 26;274(13):8383-90 - PubMed
    1. Cell. 2012 Apr 27;149(3):642-55 - PubMed
    1. Mol Cancer Res. 2015 Sep;13(9):1325-35 - PubMed
    1. Curr Biol. 2013 Jan 7;23 (1):70-5 - PubMed

Publication types

LinkOut - more resources